Automotive and Transportation Leader Pamela Fletcher Joins Sion Power as Chief Executive Officer
13.8.2024 16:00:00 EEST | Business Wire | Press release
Sion Power Corporation, a leading technology developer of next-generation batteries for electric vehicles (EV), announced today that Pamela Fletcher has joined the company as its new Chief Executive Officer. A renowned veteran of the automotive industry, Fletcher brings a proven track record of electric vehicle development and deployment, which she will leverage to accelerate the company’s transition to commercialization. She succeeds Tracy Kelley, who will transition to President and Chief Science Officer of Sion Power and continue development of world class battery technology breakthroughs.
Most recently, Fletcher served as the Senior Vice President, Chief Sustainability Officer, at Delta Air Lines where she led the airline’s sustainability and innovation efforts in service of the company’s Net Zero future. In this role she set a strategy to net zero emissions by 2050 and activated initiatives across the organization to achieve short to long-term goals, an industry first. Before her tenure at Delta Air Lines, Fletcher spent more than 15 years at General Motors where she held instrumental leadership positions, including Vice President of Global Innovation and Vice President of Electric Vehicles. She led the teams that delivered the electric Chevrolet Bolt and Chevrolet Volt to market, as well as the first true, hands-free driver assistance technology—Super Cruise.
“Again and again, Pam has been at the forefront of the automotive industry, leading award-winning product, technology, and new businesses teams. She has a passion for innovation and a track record of scaling high-growth business ventures, disrupting established industries, and attracting new customers. She has the skillset and passion to lead the commercialization of Sion Power’s breakthrough Licerion® battery technology and we’re thrilled for this next chapter,” said Stefan Jacoby, Chair, Sion Board of Directors.
“Sion Power is poised to be the first company to commercialize a lithium-metal anode through its Licerion® technology for large volume EV applications, thus disrupting the global battery industry,” said Fletcher, CEO, Sion Power. “Commercialization means more affordable electric vehicles for consumers more quickly, bolstering adoption and ultimately helping us get closer to a zero emissions world. I am honored to join this incredible company and I want to thank Tracy Kelley for his leadership to this pivotal point and all he will continue to do for our team.”
Sion Power has developed lithium-based batteries for over three decades. Over the past eight years, batteries based on their proprietary and patented technology have been its focus. This disruptive energy storage system is projected to deliver twice the specific energy when compared to today's conventional lithium-ion batteries. To learn more, visit sionpower.com.
About Sion Power
Sion Power is moving the rechargeable battery industry forward with its Licerion® technology. Licerion® is an advanced approach to lithium-metal batteries containing twice the energy in the same size and weight battery, compared to a traditional lithium-ion battery. At up to 500 Wh/kg, Licerion® batteries are produced at scale in large-format cells. As a result, Licerion® batteries have the potential to significantly enhance the performance of commercial and consumer electric vehicles. Visit Sion Power at sionpower.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240813464461/en/
Contacts
Press.Release@sionpower.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 15:03:00 EEST | Press release
Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L. Saver, MD, UCLA, and Principal Investigator of DISTALS. “What’s important is that both the device and the trial were designed specifically for distal stroke. By using a device built for these small vessels and mea
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 15:00:00 EEST | Press release
Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have faced two critical dining pain points: [Pain Point 1] The Information Gap: Most available resources are tailored for tourists, making it difficult to find the true loc
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 15:00:00 EEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 14:00:00 EEST | Press release
In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football trading cards from 2031 onward. All products will be designed and developed through Fanatics Collectibles and produced under the Topps brand. As a part of the deal, Fanatics will bring the magic to young people in every region of the world and support youth football globally by distributing more than $150 million in collect
DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 12:21:00 EEST | Press release
The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrate that personalising treatment decisions for patients with early-stage (stage II to IIIA) HER2-positive BC using the HER2DX genomic diagnostic assay can improve pat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom